IP Verse

Use Of Long-Acting Glp-1 Peptides

Patent No. EP3689365 (titled "Use Of Long-Acting Glp-1 Peptides") was filed by Novo Nordisk on Jun 21, 2013. The application was issued on Aug 6, 2025.

Patent Summary

Improved GLP-1 agonist therapy for type 2 diabetes and obesity, comprising once-weekly administration of semaglutide in doses of 0.4-1.6 mg, which provides superior glycemic control and weight loss compared to daily liraglutide doses. The therapy is characterized by a prolonged half-life, enhanced stability against gastrointestinal enzymes, and improved potency in stimulating GLP-1 receptor activity.

Patent Family

Patent Family

Patent Oppositions (7)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentative
KRAUS & LEDERER PARTGMBBMar 24, 2026KRAUS & LEDERER PARTGMBB
POLPHARMADec 24, 2025ELKINGTON AND FIFE
GALENICUM HEALTH SLUNov 20, 2025GALENICUM HEALTH SLU
DR REDDYS LABORATORIESAug 27, 2025MAIWALD
ADALVOAug 10, 2025BRAND MURRAY FULLER
GENERICS UKAug 7, 2025TER MEER STEINMEISTER & PARTNER
WUESTHOFF & WUESTHOFFAug 6, 2025WICHMANN

Dossier Documents

The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents

EP3689365

NOVO NORDISK
Application Number
EP20157813A
Filing Date
Jun 21, 2013
Status
Granted And Under Opposition
Jul 4, 2025
Publication Date
Aug 6, 2025
External Links
Slate, Register , Google Patents